I-131 MIBG(I-131 Meta-Iodobenzylguanidine) radiotherapy for malignant neuroendocrine tumors

I-131 MIBG(I-131 Meta-Iodobenzylguanidine) radiotherapy for malignant neuroendocrine tumors - I-131 MIBG radiotherapy for malignant neuroendocrine tumors

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000017057

Enrollment

Registered

2015-04-14

Start date

2015-04-14

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

malignant neuroendocrine tumors

Interventions

I-131 MIBG therapy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with unresectable I-131 positive malignant neuroendocrine tumors and with written informed consent for I-131 MIBG therapy Patients with ability for treatment in an isolation room

Exclusion criteria

Exclusion criteria: Under pregnant or breast feeding Life expectancy less than 1 month Renal disorder (GFR<30ml/min) Limited bone marrow capacity (WBC<3000,platelet<100,000) Understanding and cooperation cannnot be obtained from family members When medical staff determine that treatment cannot be properly carried out.

Design outcomes

Primary

Measure	Time frame
Therapeutic effect and side effects	—

Secondary

Measure	Time frame
The difference of uptake degree between local intraarterial injection by the reservoir and intravenous injection	—

Countries

Japan

Contacts

Public ContactMegumi Jinguji

Kagoshima university hospital Raiology

megu@m.kufm.kagoshima-u.ac.jp099-275-5417

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026